Management of Hepatic Encephalopathy

@article{Jawaro2016ManagementOH,
  title={Management of Hepatic Encephalopathy},
  author={Tara S. Jawaro and Anna Yang and Deepali Dixit and Mary Barna Bridgeman},
  journal={Annals of Pharmacotherapy},
  year={2016},
  volume={50},
  pages={569 - 577}
}
Objective: To review the management of hepatic encephalopathy (HE), including lifestyle modifying strategies and pharmacological interventions. Data Sources: A literature search of PubMed through March 2016 was conducted utilizing the keywords hepatic encephalopathy, ammonia, and cirrhosis. All published articles evaluating treatments for HE were considered. Study Selection and Data Extraction: Available English-language data from reviews, abstracts, presentations, and clinical trials of the… 
10 Citations

Figures and Tables from this paper

Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
TLDR
Evaluating the beneficial and harmful effects of pharmacotherapies that specifically target ammonia versus placebo, no intervention, or other active interventions, for the prevention and treatment of hepatic encephalopathy in people with cirrhosis found no beneficial or harmful effects.
Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy
TLDR
This review will focus on the pathophysiology of hepatic encephalopathy along with an update on therapeutic targets under investigation.
Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis
TLDR
This review will provide a comprehensive insight into the mechanisms responsible for gut-liver-brain axis dysregulation leading to HE in cirrhosis, and explore the currently available therapies and the most promising future treatments for the management of patients with HE.
Encefalopatía hepática: historia natural de la enfermedad, nueva clasificación e impacto en la calidad de vida
TLDR
The authors conclude that hepatic encephalopathy must be classified according to the underlying etiology, clinical severity, course of time, and triggering factors analyzed in the latest international guidelines.
Evaluation and management of emergencies in the patient with cirrhosis
Medical Management of Portal Hypertension and Its Complications
Portal hypertension, most commonly caused by cirrhosis, is defined as an elevated hepatic venous pressure gradient that can lead to complications including ascites, hepatic, esophageal/gastric
S-ADENOSYLMETHIONINE IN THE TREATMENT OF EXPERIMENTAL HEPATIC ENCEPHALOPATHY
Введение. Печёночная энцефалопатия (ПЭ) является наиболее тяжёлым осложнением как острой, так и хронической печёночной недостаточности. Спектр современной фармакотерапии ПЭ ограничен, поэтому поиск

References

SHOWING 1-10 OF 62 REFERENCES
Covert and Overt Hepatic Encephalopathy: Diagnosis and Management.
  • Kavish R. Patidar, J. Bajaj
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2015
A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy
TLDR
Oral zinc supplementation improved performance on the number connection test, but no evidence about other clinical or biochemical outcomes was available.
Current trends in the treatment of hepatic encephalopathy
TLDR
Clinical trials have established the efficacy of lactulose and lactitol enemas in the treatment of acute hepatic encephalopathy, and more recent data supports the benefits of rifaximin used solely and as an additional agent with fewer side effects than neomycin or metronidazole.
Mechanisms, diagnosis and management of hepatic encephalopathy
TLDR
Empiric therapy for HE is largely based on the principle of reducing the production and absorption of ammonia in the gut through administration of pharmacological agents such as rifaximin and lactulose, which are approved by the FDA for the treatment of HE.
Dopamine agents for hepatic encephalopathy.
TLDR
A review of five trials published during 1979 to 1982 found no evidence to recommend or refute the use of dopamine agents for hepatic encephalopathy, and randomised placebo-controlled clinical trials without risks of systematic errors and risks of random errors seem necessary.
Branched-chain amino acids for people with hepatic encephalopathy.
TLDR
A Cochrane systematic review including 11 randomised clinical trials on branched-chain amino acids versus control interventions has evaluated if BCAA may benefit people with hepatic encephalopathy, finding no beneficial or detrimental effects of BCAA on nausea or vomiting in a random-effects meta-analysis or on quality of life or nutritional parameters.
Sodium benzoate for treatment of hepatic encephalopathy.
TLDR
Sodium benzoate is an inexpensive adjunctive agent that can be used in addition to lactulose and rifaximin and may provide an option for some select patients with refractory HE who have failed to respond to standard therapies or who cannot afford them.
Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy
TLDR
This first large-scale investigation on hepatic encephalopathy demonstrated a similar effectiveness of the two drugs in grade 1 encephalopathic syndrome and provides a basis for drug selection in the current management of the syndrome.
The nutritional management of hepatic encephalopathy in patients with cirrhosis: International society for hepatic encephalopathy and nitrogen metabolism consensus
TLDR
Effective management of these patients requires an integrated multidimensional approach, however, further research is needed to fill the gaps in the current evidence base to optimize the nutritional management of patients with cirrhosis and HE.
...
...